Literature DB >> 11754372

Intraoperative and early postoperative chemotherapy into the abdominal cavity using gemcitabine may prevent postoperative occurence of peritoneal carcinomatosis.

Karsten Ridwelski1, Frank Meyer, Arndt Hribaschek, Udo Kasper, Hans Lippert.   

Abstract

BACKGROUND AND OBJECTIVES: Malignant tumors of various abdominal organs are blamed to be the cause of death in approximately 40% of cases per year in Western Europe. At the time of death, about half of them show peritoneal carcinomatosis which is considered an unfavorable prognostic factor. In case of peritoneal carcinomatosis, there is no curative treatment available for any of the tumors in the abdominal cavity. The aim of this experimental study was to evaluate the preventive potential of intra-operative or early postoperative local administration of gemcitabine into the abdominal cavity against peritoneal carcinomatosis.
METHODS: Peritoneal carcinomatosis was induced in male WAG rats (n = 18) by transfer of 5 x 10(6) cells of the adenocarcinoma cell line CC-531 via minilaparotomy carried out in all rats under general anesthesia. Thirty days after cell transfer, rats were sacrificed and peritoneal carcinomatosis was confirmed using histologic investigation in specimens obtained from the peritoneal site. Extension of this carcinomatosis was quantified by (i) counting tumor nodes per square centimeter (mean of several counts) and (ii) determining tumor weight (weight of the greater omentum plus the resected mesentery). Rats were subdivided into three groups (n = 6 per group): group 1 (controls); group 2, simultaneously with tumor cell transfer 24 mg/kg of gemcitabine were administered into the abdominal cavity; group 3, postoperative intraperitoneal irrigation with 24 mg/kg of gemcitabine was achieved via a previously implanted port-a-cath on days(d) 15, 21, and 27.
RESULTS: On the 30th postoperative day, all six animals of the control group showed extensive tumor growth at the peritoneum and greater omentum, indicating carcinomatosis. In contrast, none of the rats of group 2 revealed any traces of intraperitoneal tumor growth. While all rats of group 3 demonstrated intraperitoneal tumor growth, but early postoperative treatment with gemcitabine, however, resulted in a significant reduction of the number of tumor nodes and tumor weight in comparison with group 1 (controls).
CONCLUSIONS: Immediate, i.e., simultaneous intraoperative application of a cytostatic agent such as gemcitabine into the abdominal cavity may completely prevent the generation of peritoneal carcinomatosis from occuring tumor cells, whereas early postoperative locoregional chemotherapy into the abdominal cavity can only reduce the severity of the peritoneal carcinomatosis. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11754372     DOI: 10.1002/jso.10000

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  7 in total

1.  The role of intraperitoneal chemotherapy in the surgical management of pancreatic ductal adenocarcinoma: a systematic review.

Authors:  Alexandre Brind'Amour; Mitchell Webb; Marina Parapini; Lucas Sidéris; Maja Segedi; Stephen W Chung; Stéphanie Chartier-Plante; Pierre Dubé; Charles H Scudamore; Peter T W Kim
Journal:  Clin Exp Metastasis       Date:  2021-01-24       Impact factor: 5.150

2.  Host sphingosine kinase 1 worsens pancreatic cancer peritoneal carcinomatosis.

Authors:  Hiroaki Aoki; Masayo Aoki; Eriko Katsuta; Rajesh Ramanathan; Michael O Idowu; Sarah Spiegel; Kazuaki Takabe
Journal:  J Surg Res       Date:  2016-07-09       Impact factor: 2.192

3.  Multimodal approach for treatment of peritoneal surface malignancies in a tumour-bearing rat model.

Authors:  Wieland Raue; Maik Kilian; Chris Braumann; Vladimir Atanassow; Anna Makareinis; Sonja Caldenas; Wolfgang Schwenk; Jens Hartmann
Journal:  Int J Colorectal Dis       Date:  2009-11-10       Impact factor: 2.571

4.  Safety of perioperative hyperthermic intraperitoneal chemotherapy with gemcitabine in patients with resected pancreatic adenocarcinoma: a pilot study of the clinical trial EudraCT 2016-004298-41.

Authors:  David Padilla-Valverde; Esther García-Santos; Susana Sanchez; Carmen Manzanares; Marta Rodriguez; Lucia González; Alfonso Ambrós; Juana M Cano; Leticia Serrano; Raquel Bodoque; Teresa Vergara; Jesus Martin
Journal:  J Gastrointest Oncol       Date:  2021-04

5.  Hyperthermic intra-operative intraperitoneal chemotherapy as an adjuvant to pancreatic cancer resection.

Authors:  Antonios-Apostolos K Tentes
Journal:  J Gastrointest Oncol       Date:  2021-04

6.  Preliminary results of hyperthermic intraperitoneal intraoperative chemotherapy as an adjuvant in resectable pancreatic cancer.

Authors:  Antonios-Apostolos K Tentes; Dimitrios Kyziridis; Stylianos Kakolyris; Nicolaos Pallas; Georgios Zorbas; Odysseas Korakianitis; Christos Mavroudis; Nicolaos Courcoutsakis; Panos Prasopoulos
Journal:  Gastroenterol Res Pract       Date:  2012-05-27       Impact factor: 2.260

7.  A Prospective, Phase I/II, Open-Label Pilot Trial to Assess the Safety of Hyperthermic Intraperitoneal Chemotherapy After Oncological Resection of Pancreatic Adenocarcinoma.

Authors:  Can Yurttas; Philipp Horvath; Imma Fischer; Christoph Meisner; Silvio Nadalin; Ingmar Königsrainer; Alfred Königsrainer; Stefan Beckert; Markus W Löffler
Journal:  Ann Surg Oncol       Date:  2021-06-15       Impact factor: 5.344

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.